Table 1.
Gardasil | Cervarix | |
---|---|---|
Manufacturer | Merck | GlaxoSmithKline |
HPV types | 16, 18, 6, 11 | 16, 18 |
Amount of HPV L1 protein | 20 μg HPV-6 40 μg HPV-11 40 μg HPV-16 20 μg HPV-18 |
20 μg HPV-16 20 μg HPV-18 |
Adjuvant | 225 μg aluminum hydroxyphosphate sulfate | AS04 composed of: 500 μg aluminum hydroxide 50 μg MPL (3-O-desacyl-4′-monophosphoryl lipid A) |
FDA Approval in US | June 2006 | October 2009 |
Regimen | 3 doses: Months 0, 2, 6 | 3 doses: Months 0, 1, 6 |
Cost | $120 USD per dose | $100 USD per dose |
Antigen Source | Saccharomyces cerevisiae (bread yeast), expressing L1 | Trichoplusia ni insect cell line infected with L1 encoding recombinant baculovirus |
Indications | Girls and young women: age 9 – 26 For the prevention of cervical, vulvar, vaginal cancer, and anal cancer and associated pre-cancerous lesions and genital warts Boys and young men: ages 9 – 26 For the prevention of anal cancer and associated pre-cancerous lesions, and genital warts |
Girls and young women: age 10 – 25 For the prevention of cervical cancer and associated pre-cancerous lesions |
Duration of protection | At least 6.4 years [60,61] | At least 8.4 years [40,63] |
Antibody titers | HPV-16: 2.3 – 4.8 times higher for Cervarix compared with Gardasil, across all age groups HPV-18: 6.8 – 9.1 times higher with Cervarix [64] |